GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023
The company has reported total income of Rs. 58.42 crores during the period ended March 31, 2023
Sun Pharma said had a teleconference call with the US Food and Drug Administration (USFDA) regarding a pulmonary embolism (serious adverse events) occurring at the 12 mg dose
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
Agasta Software is engaged in research, development and commercialization of medical devices
The respective product approval is based on Revlimid Capsules, 5mg, 10mg, 15mg, 25mg and 2.5mg, 20mg as a reference product
Subscribe To Our Newsletter & Stay Updated
